Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension

Objective: Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a considerably higher cost. This study evaluated the co...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenxing Dong (Author), Zhe Zhang (Author), Mingming Chu (Author), Peng Gu (Author), Min Hu (Author), Lulu Liu (Author), Jingbin Huang (Author), Rong Zhang (Author)
Format: Book
Published: Frontiers Media S.A., 2023-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available